Amyloid-β Oligomers Relate to Cognitive Decline in Alzheimer's Disease

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Alzheimer's Disease

• Publication date

  2015-03-03

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.3233/JAD-142136PMID 25547634
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnosis and management of dementia with Lewy bodies

  2017cited by this paper
• A label-free electrical impedimetric biosensor for the specific detection of Alzheimer's amyloid-beta oligomers.

  2014cited by this paper
• A Sensitive Aβ Oligomer Assay Discriminates Alzheimer's and Aged Control Cerebrospinal Fluid

  2014cited by this paper
• Correlation of Aβ oligomer levels in matched cerebrospinal fluid and serum samples.

  2013cited by this paper
• Brain amyloid-β oligomers in ageing and Alzheimer's disease.

  2013cited by this paper
• A Luminex Assay Detects Amyloid β Oligomers in Alzheimer’s Disease Cerebrospinal Fluid

  2013cited by this paper
• Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide

  2013cited by this paper
• The Amyloid-β Oligomer Count in Cerebrospinal Fluid is a Biomarker for Alzheimer's Disease

  2013cited by this paper
• Systemic vaccination with anti‐oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg‐AD mice

  2013cited by this paper
• Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease

  2013cited by this paper
• Amyloid-β oligomer detection by ELISA in cerebrospinal fluid and brain tissue.

  2013cited by this paper
• Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults.

  2013cited by this paper
• Methods for Analysis of Amyloid-β Aggregates

  2012cited by this paper
• Amyloid-β Oligomers in Cerebrospinal Fluid are Associated with Cognitive Decline in Patients with Alzheimer's Disease

  2012cited by this paper
• Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers.

  2012cited by this paper
• Membrane and surface interactions of Alzheimer’s Aβ peptide – insights into the mechanism of cytotoxicity

  2011cited by this paper
• Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

  2011cited by this paper
• Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration

  2011cited by this paper
• The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: neuropathological, epidemiological and genetic evidence.

  2011cited by this paper
• CSF biomarkers for Alzheimer's disease: current utility and potential future use.

  2011cited by this paper
• Single-Particle Detection System for Aβ Aggregates: Adaptation of Surface-Fluorescence Intensity Distribution Analysis to Laser Scanning Microscopy

  2010cited by this paper
• High‐molecular‐weight β‐amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients

  2010cited by this paper
• Amyloid oligomers: formation and toxicity of Aβ oligomers

  2010cited by this paper
• Generation and Therapeutic Efficacy of Highly Oligomer-Specific β-Amyloid Antibodies

  2010cited by this paper
• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking

  2009cited by this paper
• β-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin

  2009cited by this paper
• Quantification of amyloid-beta 40 in cerebrospinal fluid.

  2009cited by this paper
• Photo-induced cross-linking of unmodified proteins (PICUP) applied to amyloidogenic peptides.

  2009cited by this paper
• Neurotoxic effect of oligomeric and fibrillar species of amyloid-beta peptide 1-42: involvement of endoplasmic reticulum calcium release in oligomer-induced cell death.

  2008cited by this paper
• Effect of different salt ions on the propensity of aggregation and on the structure of Alzheimer's abeta(1-40) amyloid fibrils.

  2007cited by this paper
• Detection of Amyloid-β Oligomers in Human Cerebrospinal Fluid by Flow Cytometry and Fluorescence Resonance Energy Transfer

  2007cited by this paper
• Detection of amyloid-beta oligomers in human cerebrospinal fluid by flow cytometry and fluorescence resonance energy transfer.

  2007cited by this paper
• Different Conformations of Amyloid β Induce Neurotoxicity by Distinct Mechanisms in Human Cortical Neurons

  2006cited by this paper
• Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins.

  2006cited by this paper
• A specific amyloid-β protein assembly in the brain impairs memory

  2006cited by this paper
• A specific amyloid-beta protein assembly in the brain impairs memory.

  2006cited by this paper
• Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2005cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

  2002cited by this paper
• Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.

  1999cited by this paper
• Mild Cognitive Impairment Clinical Characterization and Outcome

  1999cited by this paper
• Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

  1998cited by this paper
• Frontotemporal lobar degeneration

  1998cited by this paper
• Vascular dementia

  1993cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975influential reference

• Structural analysis of the asymmetric interaction between amyloid β42 and α-Synuclein: Amyloid β42 oligomers promote α-synuclein aggregation while α-synuclein inhibits amyloid β42 aggregation.

  2026cites this paper
• The study of plaques and tangles makes few and inaccurate predictions about the main features of cognitive disorders: A narrative review

  2025cites this paper
• Plasma amyloid‐β Oligomerization tendency as a potential predictor for conversion from mild cognitive impairment to Alzheimer’s dementia: Findings from the GMCII cohort

  2024cites this paper
• Advances in nanoprobes for molecular MRI of Alzheimer's disease.

  2024cites this paper
• Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology

  2024cites this paper
• Sugar distributions on gangliosides guide the formation and stability of amyloid-β oligomers

  2023cites this paper
• α-Synuclein Aggregation Is Triggered by Oligomeric Amyloid-β 42 via Heterogeneous Primary Nucleation

  2023cites this paper
• The shift to a proteinopenia paradigm in neurodegeneration.

  2023cites this paper
• Sugar distributions on gangliosides guide the formation and stability of amyloid-β oligomers.

  2023cites this paper
• CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease

  2023cites this paper
• Senescence-related impairment of autophagy induces toxic intraneuronal amyloid-β accumulation in a mouse model of amyloid pathology

  2023cites this paper
• Ablation of cell-specific cholesterol synthesis affects cerebral β-amyloidosis

  2023cites this paper
• A Novel Serum‐Based Diagnosis of Alzheimer's Disease Using an Advanced Phage‐Based Biochip

  2023cites this paper
• Telomere-induced senescence increases aberrant intraneuronal amyloid-β accumulation by impairing autophagy in a mouse model of Alzheimer’s disease

  2022cites this paper
• Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer’s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach

  2022cites this paper
• Should we lower or raise levels of amyloid-β in the brains of Alzheimer patients?

  2022cites this paper
• Clinical and Molecular Findings in a Turkish Family Who Had a (c.879-1G>A) Splicing Variant in PSEN1 Gene with A Rare Condition: The Variant Alzheimer's Disease with Spastic Paraparesis.

  2022cites this paper
• Proteins Do Not Replicate, They Precipitate: Phase Transition and Loss of Function Toxicity in Amyloid Pathologies

  2022cites this paper
• Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease.

  2022cites this paper
• Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer’s disease brain extracts

  2022cites this paper
• Breakdown of the blood–brain barrier: A mediator of increased Alzheimer's risk in patients with metabolic disorders?

  2021cites this paper
• Biophysical characteristics of lipid‐induced Aβ oligomers correlate to distinctive phenotypes in transgenic mice

  2021cites this paper
• An evaluation of the self-assembly enhancing properties of cell-derived hexameric amyloid-β

  2021cites this paper
• Soluble Amyloid-β Consumption in Alzheimer’s Disease

  2021cites this paper
• Importance of extracellular vesicle secretion at the blood–cerebrospinal fluid interface in the pathogenesis of Alzheimer’s disease

  2021cites this paper
• Cell-derived hexameric β-amyloid: a novel insight into composition, self-assembly and nucleating properties

  2020cites this paper
• Clinical significance of fluid biomarkers in Alzheimer’s Disease

  2020cites this paper
• Implications of Oligomeric Amyloid-Beta (oAβ42) Signaling through α7β2-Nicotinic Acetylcholine Receptors (nAChRs) on Basal Forebrain Cholinergic Neuronal Intrinsic Excitability and Cognitive Decline

  2020cites this paper
• Protein Solubility Predictions Using the CamSol Method in the Study of Protein Homeostasis.

  2019cites this paper
• Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer’s disease

  2019cites this paper
• Challenges in understanding the structure/activity relationship of Aβ oligomers

  2019cites this paper
• Specific Keratinase Derived Designer Peptides Potently Inhibit A β Aggregation Resulting in Reduced Neuronal Toxicity and Apoptosis.

  2019cites this paper
• Oxidative Stress in Alzheimer’s Disease: Molecular Hallmarks of Underlying Vulnerability

  2019cites this paper
• Serum levels and mutual correlations of amyloid β in patients with depression

  2019cites this paper
• Research and Development of Vaccines for Alzheimer ' s Disease

  2019cites this paper
• Human cerebrospinal fluid 6E10-immunoreactive protein species contain amyloid precursor protein fragments

  2019cites this paper
• The National Institute on Aging—Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials

  2018cites this paper
• Amyloid β oligomers (AβOs) in Alzheimer’s disease

  2018cites this paper
• Counteracting the effects of TNF receptor‐1 has therapeutic potential in Alzheimer's disease

  2018cites this paper
• Propagation of an Aβ Dodecamer Strain Involves a Three-Step Mechanism and a Key Intermediate.

  2018cites this paper
• Neuroprotective Effect of Caffeic Acid Phenethyl Ester in A Mouse Model of Alzheimer’s Disease Involves Nrf2/HO-1 Pathway

  2018cites this paper
• The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade

  2018cites this paper
• Investigating therapeutic strategies in a preclinical model for Alzheimer's disease

  2017cites this paper
• Phytochemicals as inhibitors of NF‐&kgr;B for treatment of Alzheimer's disease

  2017cites this paper
• N‐Stearoylethanolamine protects the brain and improves memory of mice treated with lipopolysaccharide or immunized with the extracellular domain of &agr;7 nicotinic acetylcholine receptor

  2017cites this paper
• Potential biomarkers and novel pharmacological targets in protein aggregation‐related neurodegenerative diseases

  2017cites this paper
• A vaccine with Aβ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer’s disease

  2017cites this paper
• Selecting Aβ isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel.

  2017cites this paper
• Methods for the Specific Detection and Quantitation of Amyloid-β Oligomers in Cerebrospinal Fluid

  2016cites this paper
• Prediction of Free and Cued Selective Reminding Test Performance Using Volumetric and Amyloid-Based Biomarkers of Alzheimer’s Disease

  2016cites this paper
• Peripheral Immune Signatures in Alzheimer Disease.

  2016cites this paper
• Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases—From pathophysiology to clinical practice

  2016cites this paper
• Advanced diagnostics and therapeutics for Alzheimer’s disease

  2016cites this paper
• Insulin and the Future Treatment of Alzheimer's Disease.

  2016cites this paper
• Alpha-tocopherol quinine ameliorates spatial memory deficits by reducing beta-amyloid oligomers, neuroinflammation and oxidative stress in transgenic mice with Alzheimer's disease.

  2016cites this paper
• The Role of α7 Nicotinic Acetylcholine Receptors and α7-Specific Antibodies in Neuroinflammation Related to Alzheimer Disease.

  2016cites this paper
• Amyloid-β and amyloid associated proteins in the pathology and diagnosis of Alzheimer's disease

  2016cites this paper
• Review of the Evidence that Transcranial Electromagnetic Treatment will be a Safe and Effective Therapeutic Against Alzheimer’s Disease

  2016cites this paper
• The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events

  2015cites this paper
• Brain region-specific microglial phenotypes and responses in Parkinson’s disease

  2015cites this paper
• Leptin attenuates the detrimental effects of β-amyloid on spatial memory and hippocampal later-phase long term potentiation in rats.

  2015cites this paper
• Spiroindole Alkaloids and Spiroditerpenoids from Aspergillus duricaulis and Their Potential Neuroprotective Effects.

  2015cites this paper